Home > Investor Relations > Financial Results > Revenue by Product

Revenue by Product

(Billions of Yen)
  2013 2014 2015
Sales 401.3 436.9 468.4
  Excl.Tamiflu® 390.2 423.8 460.2
  Domestic 329.2 349.5 378.0
  Oncology 172.4 188.9 215.7
  Avastin® 75.4 82.3 93.8
Herceptin® 30.9 31.2 32.7
Rituxan® 26.2 26.2 29.0
Tarceva® 10.4 11.5 11.6
Xeloda® 11.3 10.4 11.1
Perjeta®* 2.4 9.1 10.6
Kadcyla®* - 4.0 7.3
Alecensa®* - 1.4 8.0
Neutrogin® 8.1 5.9 4.9
Zelboraf®* - - 0.5
Other products 7.6 6.9 6.1
Bone and joint diseases 60.6 69.6 79.4
  Actemra® 20.4 24.1 26.8
Edirol® 15.0 19.2 23.1
Suvenyl® 11.9 10.7 10.5
Bonviva®* 0.5 3.4 5.4
Alfarol® 6.4 4.9 4.2
Other products 6.3 7.4 9.5
Renal diseases 48.9 44.7 45.4
  Mircera® 22.5 22.6 23.8
Oxarol® 12.2 12.2 12.9
Epogin® 10.5 6.6 5.9
Other products 3.7 3.4 2.8
Transplant, Immunology, and Infectious diseases 18.8 20.8 15.9
  CellCept® 7.2 6.5 7.0
Pegasys® 5.5 7.0 1.9
Copegus® 1.3 3.1 2.9
Other products 4.8 4.2 4.0
Others 28.6 25.6 21.7
  Sigmart® 8.6 6.4 5.2
Other products 20.0 19.2 16.6
Overseas 61.1 74.3 82.2
    Actemra® 43.2 55.7 63.6
To Roche 42.9 55.1 62.6
Neutrogin® 14.7 15.7 14.8
Aloxi®** - - 0.3
Alecensa®** - - 0.5
Akynzeo®** - - 0.0
Other products 3.1 2.9 3.0
Tamiflu® 11.0 13.0 8.2
  Ordinary use 10.1 12.9 8.2
Govt. stockpiles etc. 0.9 0.2 0.0
Royalties and other operating income 22.4 24.2 30.4
Revenues (total) 423.7 461.1 498.8
    Domestic 350.8 372.9 390.0
Overseas 72.9 88.2 108.8

*Perjeta (launched in September 2013), Kadcyla (launched in April 2014), Alecensa (launched in September 2014), Zelboraf (launched in February 2015), Bonviva (launched in August 2013 <IV>)
**Aloxi (launched in January 2015 (UK)), Alecensa (launched in December 2015 (US)), Akynzeo (launched in September 2015 (UK), December 2015 (Ireland))

Sales by Strategic Field (FY2015)

Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.